3VC

3VC is a Vienna-based growth-stage fund that backs Series A and Series B software companies across Austria, Germany, and Switzerland, with a generalist software thesis and no stated healthcare specialization. Physician founders should read this entry as informational rather than as a target list entry, because healthcare is not where 3VC concentrates its diligence or its capital.

The thesis is DACH-region software at the point where companies have proven product-market fit and need a real growth-stage partner. That means the typical 3VC company has commercial revenue, a repeatable go-to-market motion, and a need for capital to expand across European markets or invest in a second product line. Healthcare-adjacent software is plausible only if the company looks indistinguishable from a horizontal SaaS business in its metrics and its operating model. The fund does not publish a healthcare-specific portfolio, and the public materials position 3VC as a generalist with a CEE and DACH gravity.

Check sizes run from 5 million to 25 million dollars, which is a clear Series A and Series B band. That places 3VC out of reach for pre-seed and seed founders, and a poor fit for early-stage clinical AI or medical-device companies that have not yet generated meaningful revenue. The fund leads or co-leads, takes board seats, and expects the standard governance structure of a growth-stage round.

The team is not detailed publicly, but the fund’s positioning suggests a small partner group that sources directly across the DACH ecosystem and works hands-on with portfolio companies post-investment.

Approach 3VC only if you are running a software company at Series A or B with a strong DACH presence or expansion thesis, and your healthcare exposure is secondary to a horizontal software story. If you are a physician founder with a clinical AI tool that genuinely looks like enterprise SaaS in its sales motion and unit economics, there may be a conversation, but it will hinge on the metrics rather than on the clinical narrative. Warm introductions from Vienna, Berlin, Zurich, or Munich operators, or from other European Series A funds that have co-invested with 3VC, are the most reliable path in. Avoid pitching early-stage, regulated, or clinically intensive plays; the fund is not staffed for that diligence. Time the outreach when you have at least a few million in annual recurring revenue and a clear case for why DACH growth capital is the right next step.